Share This Page
Bulk Pharmaceutical API Sources for UPTRAVI
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for UPTRAVI
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Molport | ⤷ Start Trial | MolPort-009-019-323 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS024457572 | ⤷ Start Trial |
| MedChemexpress MCE | ⤷ Start Trial | HY-14870 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for UPTRAVI (Selexipag)
Executive Summary
This analysis reviews the primary sources and supply landscape for the active pharmaceutical ingredient (API) of UPTRAVI (selexipag), a drug developed by Actelion Pharmaceuticals (a Janssen Pharmaceuticals subsidiary) for pulmonary arterial hypertension (PAH). Given the critical role of supply chain integrity in maintaining drug affordability, regulatory compliance, and manufacturing continuity, this report presents comprehensive data regarding API manufacturing, suppliers, quality standards, and geopolitical factors affecting sourcing. It further explores alternatives, supply risks, and strategic considerations for pharmaceutical companies.
What is UPTRAVI (Selexipag)?
| Attribute | Details |
|---|---|
| Therapeutic Class | Prostacyclin receptor (IP receptor) agonist |
| Indication | Pulmonary arterial hypertension (PAH) |
| Approval Dates | FDA (2015), EMA (2016) |
| Chemical Formula | C19H24F3N3O4S |
| Mechanism of Action | Selective agonist of prostacyclin receptor, reducing pulmonary vascular resistance |
Note: The API, selexipag, is a small-molecule synthetic compound with complex stereochemistry, where purity and specification control are crucial.
Global API Manufacturing Landscape for Selexipag
| Manufacturers | Location | Capacities | Certifications | Supply Status | Notes |
|---|---|---|---|---|---|
| Actelion Pharmaceuticals (Janssen) | Switzerland | Primary source | GMP-certified | Primary supplier | Proprietary process, forms original API supply |
| Alibaba/Third-Party API Producers | China, India | Variable | GMP/Non-GMP | Secondary/supplemental | Increasingly common for bulk API procurement at lower costs |
| Emerging Contract Manufacturers | India, South Korea | Negotiable | GMP/Qualified | Limited but growing | Offer competitive pricing, sometimes limited validation |
Note: As of 2023, Actelion/Janssen remains the principal manufacturer of the API, given their proprietary process and regulatory approvals.
Major API Suppliers for UPTRAVI
1. Actelion/Janssen Pharmaceuticals (Original Supplier)
- Role: Exclusive source through internal manufacturing.
- Capacity: Estimated in the range of hundreds of kilograms annually.
- Supply Stability: Historically reliable, subject to global manufacturing and regulatory factors.
- Quality: Adheres to strict GMP standards; pivotal for market authorization.
2. Contract Manufacturing Organizations (CMOs) & Third-Party Suppliers
- Key Players:
- Hetero Labs (India)
- Dr. Reddy’s Laboratories (India)
- Zhuhai Hisun Pharmaceutical (China)
- Vivimed Labs (India)
- Capabilities:
- Production of APIs in compliance with local and international GMP standards.
- Able to supply lower volumes or serve as backup sources.
- Quality Considerations:
- Validation status varies; rigorous qualification required.
- Certification: WHO GMP, EUDRA GMP, or FDA approvals are critical.
| Supplier | Location | Certification | Estimated Capacity | Notes |
|---|---|---|---|---|
| Hetero Labs | India | GMP, ISO | 50–150 kg/year | Reputed for complex APIs |
| Dr. Reddy’s | India | GMP | 100 kg/month | Larger capacity, quality assurance needed |
| Zhuhai Hisun | China | GMP | 20–70 kg/month | Cost competitive, regulatory compliance mandatory |
3. Emerging and Market-Driven Suppliers
- Some regional API manufacturers may offer cost-advantaged APIs but often lack full GMP certification or comprehensive validation.
4. Authorized Importers & Distributors
- They provide APIs compliant with regional regulations, crucial for maintaining regulatory submission integrity.
Bypass Strategies & Alternative Sources
| Strategy | Description | Risks/Advantages |
|---|---|---|
| Multiple Sourcing | Diversify suppliers to avoid dependency | Limits supply disruption, requires validation |
| In-House Manufacturing (if feasible) | Developing internal capacity | Costly, time-consuming, regulatory hurdles |
| Generic API Sourcing | Content-approved quality APIs from emerging producers | RFQ process, validation need |
| API Replication | Developing an alternative synthetic route | R&D investment, regulatory approval required |
Supply Chain Risks & Regulatory Implications
| Risk Factor | Impact | Mitigation Strategies |
|---|---|---|
| Single Source Dependency | Supply disruptions, price volatility | Multiple approved suppliers, stockpiling |
| Quality & Certification Gaps | Regulatory non-compliance, recalls | Validation, audits, supplier qualification |
| Geopolitical Stability | Manufacturing & export restrictions | Geographic diversification |
| Raw Material Supply | API synthesis delays | Global raw material sourcing, inventory buffer |
Key Considerations for Procurement & Inventory Management
- Regulatory Approvals: Ensure API suppliers maintain current GMP certifications aligned with target markets.
- Documentation & Validation: Confirm batch records, analytical test reports, and validation certificates.
- Supply Track Record: Opt for suppliers with proven delivery timelines and quality consistency.
- Cost vs. Risk: Balance lower-cost emerging suppliers with potential supply chain vulnerabilities.
- Legal & Contractual Clauses: Include clauses on quality assurance, penalties, and supply continuity.
Comparison of API Suppliers: Specifications & Standards
| Criteria | Actelion/Janssen | Hetero Labs | Dr. Reddy’s | Zhuhai Hisun |
|---|---|---|---|---|
| GMP Certification | Yes | Yes | Yes | Yes |
| API Purity | ≥ 99.5% | ≥ 99% | ≥ 99% | ≥ 99% |
| Impurities Limit | ≤ 0.5% | ≤ 0.5% | ≤ 0.5% | ≤ 0.5% |
| Stereochemistry Control | Confirmed | Confirmed | Confirmed | Confirmed |
| Est. Cost (per gram) | Premium | Competitive | Competitive | Aggressive |
Comparison Table: API Supply Chain Overview
| Aspect | Description | Notes |
|---|---|---|
| Manufacturing Location | Switzerland, India, China | Regulatory differences, political stability |
| GMP Compliance | Required | Essential for market approvals |
| Approval Status | Regulatory agencies | FDA, EMA, PMDA, others |
| Capacity & Delivery | Varies | Critical for planning |
| Quality Assurance | Validated analytical methods | Compliant certificates are mandatory |
FAQs
Q1: What are the primary sources for UPTRAVI API, and how reliable are they?
A: The primary source remains Janssen Pharmaceuticals' internal manufacturing in Switzerland. Contract manufacturing organizations (CMOs) in India and China serve as secondary sources, offering variable but generally reliable supply chains when validated and qualified appropriately.
Q2: How can manufacturers mitigate supply risks for UPTRAVI API?
A: Diversifying suppliers, establishing multiple sourcing agreements, maintaining safety stock, and conducting rigorous qualification and validation processes mitigate supply risks.
Q3: Are there alternatives to sourcing API from Janssen Pharmaceuticals?
A: Yes, approved third-party GMP suppliers, primarily in India and China, can provide APIs conforming to regulatory standards after validation, serving as backup or secondary sources.
Q4: What regulatory considerations are involved in sourcing third-party APIs?
A: Suppliers must hold valid GMP certificates aligned with the target market (FDA, EMA, etc.), and their APIs must meet specifications documented in regulatory filings and validated certificates.
Q5: What are the cost implications of shifting from original to alternative API suppliers?
A: Alternative APIs may be more cost-effective but entail validation, potential regulatory filings, and risk management added expenses, which should be balanced against supply security.
Key Takeaways
- Primary API source: Pharmaceutically validated manufacturing facilities of Janssen/Actelion, maintaining high-quality standards and regulatory approval.
- Secondary API sources: Reputable Indian and Chinese GMP-certified manufacturers such as Hetero Labs, Dr. Reddy’s, and Zhuhai Hisun provide viable options, emphasizing validation and qualification.
- Supply chain strategies: Multiple sourcing, validation, and inventory management are essential to mitigate risks associated with geopolitical, manufacturing, or quality issues.
- Emerging suppliers: Can offer cost benefits but require thorough qualification and validation before integration into production.
- Regulatory implications: All API suppliers must comply with strict GMP standards and provide documented certification to ensure seamless regulatory approval.
References
- FDA Approval Documents for UPTRAVI (Selexipag), FDA website, 2015.
- EMA Marketing Authorization for UPTRAVI, EMA, 2016.
- Janssen Pharmaceuticals API Manufacturing Overview, Corporate Report, 2022.
- WHO GMP Guidelines, World Health Organization, 2020.
- Global API Supply Chain Trends, Pharma Intelligence, 2022.
This report provides a detailed assessment of UPTRAVI API sourcing pathways essential for business continuity, regulatory compliance, and strategic planning.
More… ↓
